Viking Therapeutics, Inc. (VKTX)
| Market Cap | 2.89B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -171.55M |
| Shares Out | 112.44M |
| EPS (ttm) | -1.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,763,107 |
| Open | 24.61 |
| Previous Close | 24.36 |
| Day's Range | 24.53 - 26.74 |
| 52-Week Range | 18.92 - 81.73 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 86.92 (+238.34%) |
| Earnings Date | Jul 23, 2025 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $86.92, which is an increase of 238.34% from the latest price.
News
Viking Therapeutics: Panic Creates Opportunity
Viking Therapeutics' stock plunged over 40% after misunderstood Phase 2 oral weight-loss drug data, despite results showing strong short-term efficacy versus market leaders. The Phase 2 trial demonstr...
Viking Therapeutics: What's Happening With VKTX Stock?
Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over ...
Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'
Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as investors balked at tolerability concerns and dropout rates. The Phase 2...
Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data
Mizuho's Jared Holz joins 'Fast Money' to talk Viking Therapeutics' massive stock drop on new obesity pill data.
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
Investors appear disappointed with Viking Therapeutics Inc.'s VKTX data from its Phase 2 trial of an obesity pill.
The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin
Justin Zelin, BTIG senior biotech analyst, joins 'The Exchange' to discuss GLP-1's and the share decline for Viking Therapeutics and why he's still bullish the stock.
Viking Therapeutics plummets on new obesity drug data. Here's a breakdown
CNBC's Angelica Peebles joins 'Money Movers' to discuss Viking Therapy shares plummeting on new obesity drug data.
Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results
Viking Therapeutics (VKTX) shares cratered nearly 45% Tuesday when the biopharma firm reported study of its experimental weight-loss pill raised concerns about side effects.
Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success
Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite be...
Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data
The once-daily pill VK2735 had lower weight-loss results on average compared to Eli Lilly's orforglipron, which was tested over 72 weeks. The highest dose of Eli Lilly's once-daily treatment helped pa...
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Shares of Viking Therapeutics fell more than 30% on Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. While the weight loss caused by Viking's p...
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
On Tuesday, Viking Therapeutics Inc. VKTX released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent ...
Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.
Viking Therapeutics on Tuesday announced that a trial showed its oral weight-loss drug works — and like a larger rival, its stock price immediately suffered.
Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'
Viking Therapeutics stock (NASDAQ: VKTX) plunged 37% in pre-market trading on Tuesday following the release of much-anticipated results from its mid-stage trial for the oral weight loss drug VK2735. T...
Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study
Viking Therapeutics said on Tuesday its experimental weight-loss pill helped patients with obesity lose nearly 12.2% of their body weight on average over 13 weeks in a mid-stage study.
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weigh...
Viking Therapeutics: Still On Track
Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline and the massive potential of the GLP-1 market. Early clinical data for VK2735 is competitive, even o...
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics' stock has outperformed the S&P 500 since its April lows, marking a solid turnaround. The company's dual-track approach (injectables and oral) for VK2735 positions it well against ...
Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer C...
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in Obesity Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2...
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time SAN DIEGO , July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage bi...
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with $8...
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics, Inc. VKTX on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulino...
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO , June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:...